

1 **Characteristics and outcomes of cases of children and adolescents with**  
2 **pediatric inflammatory multisystem syndrome in a tertiary care center**  
3 **in Mexico City**

4 **Ricardo Gil Guevara**<sup>1†</sup>, **María de Lourdes Marroquín Yáñez**<sup>2 †</sup>, **Rodolfo Norberto Jiménez-**  
5 **Juárez**<sup>3,4</sup>, **Víctor Olivar Lopez**<sup>1</sup>, **Adrián Chávez Lopez**<sup>2</sup>, **Juan José Luis Sienra Monge**<sup>5</sup>,  
6 **Lourdes Maria del Carmen Jamaica Balderas**<sup>6</sup>, **Silvia Alexandra Martínez Herrera**<sup>1</sup>, **Clemen**  
7 **Domínguez-Barrera**<sup>3</sup>, **Julio Erdmenger Orellana**<sup>7</sup>, **Horacio Márquez González**<sup>8</sup>, **Miguel**  
8 **Klünder-Klünder**<sup>9</sup>, **Jaime Nieto Zermeño**<sup>10</sup>, **Mónica Villa Guillen**<sup>10</sup>, **Nadia González García**<sup>11</sup> \*,  
9 **Maria F Castilla-Peon**<sup>12</sup> \*

10 †These authors have contributed equally to this work and share first authorship

11 \*These authors have contributed equally to this work and are both corresponding authors

12  
13 <sup>1</sup> Emergency Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional  
14 de Salud, Mexico City, Mexico

15 <sup>2</sup> Pediatric Intensive Care Unit, Hospital Infantil de Mexico Instituto Nacional de Salud , Mexico  
16 City, Mexico<sup>3</sup> Infectious Diseases Department, Hospital Infantil de Mexico Federico Gomez Instituto  
17 Nacional de Salud , Mexico City, Mexico.

18 <sup>3</sup> Department of Infectious Diseases, Hospital Infantil de Mexico Federico Gomez Instituto Nacional  
19 de Salud , Mexico City, Mexico.

20 <sup>4</sup> Department of Pediatrics, Infectious Diseases Hospital, UMAR National Medical Center “La Raza”,  
21 Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico

22 <sup>5</sup> Ambulatory Pediatrics, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud  
23 Instituto Nacional de Salud , Mexico City, Mexico.

24 <sup>6</sup> Respiratory Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional  
25 de Salud , Mexico City, Mexico.

26 <sup>7</sup> Cardiology Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud,  
27 Mexico City, Mexico

28 <sup>8</sup> Department of Clinical Research, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de  
29 Salud , Mexico City, Mexico

30 <sup>9</sup> Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud ,  
31 Mexico City, Mexico

32 <sup>10</sup> Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud , Mexico City, Mexico

33 <sup>11</sup> Neurosciences Research Laboratory, Hospital Infantil de Mexico Federico Gomez Instituto  
34 Nacional de Salud, Mexico City, Mexico

35 <sup>12</sup> Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud,  
36 Mexico City, Mexico

37  
38 **\* Correspondence:**

39 Maria F. Castilla-Peon [fernandacastillapeon@gmail.com](mailto:fernandacastillapeon@gmail.com)

40 Nadia Gonzalez-García [nadia.him@gmail.com](mailto:nadia.him@gmail.com)

41

## 42 **Abstract**

43 **Background:** pediatric inflammatory multisystem syndrome (PIMS) is a complication of severe acute  
44 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children that resembles Kawasaki  
45 syndrome and poses children at high risk of cardiorespiratory instability and/or cardiac damage. This  
46 study aims to describe the clinical presentation and outcomes of patients with PIMS in Mexico City.

47 **Methods:** this was an observational study (May 1, 2020, to September 30, 2021) of children with  
48 PIMS according to Centers of Disease Control and Prevention case definition criteria, hospitalized in  
49 a single tertiary care pediatric center in Mexico City. Demographic characteristics, epidemiological  
50 data, medical history, laboratory tests, cardiology evaluations, treatment, and clinical outcomes were  
51 analyzed.

52 **Results:** Seventy-five cases fulfilled case-definition criteria for PIMS (median age 10.9 years, IQR:  
53 5.6-15.6). Fifteen (20%) had a severe underlying disease. Forty-eight cases (64%) were admitted to  
54 the intensive care unit, 33 (44%) patients required invasive mechanical ventilation, and 39 (52%)  
55 received vasopressor support. Two distinct groups of patients were identified: cluster 1 (n=60) who  
56 had rash or gastrointestinal symptoms and cluster 2 (n=15) with predominantly respiratory  
57 manifestations. Two cases (2.7%) died, both with severe underlying conditions. Five cases (6.7%)  
58 developed coronary aneurysms, all of them from cluster 1.

59 **Conclusion:** clinical manifestations and outcomes are in general comparable what has been  
60 previously reported in international series. In our series, there was a high proportion of patients with  
61 severe respiratory involvement and positive RT-PCR SARS-CoV-2 and a low frequency of coronary  
62 aneurysms which suggests a possible higher proportion of children with severe acute COVID-19 in  
63 our included cases.

64 **Keywords:** pediatric multisystem inflammatory disease, COVID-19, SARS-CoV-2, children,  
65 coronary aneurysms, Mexico.

66

## 67 **Introduction**

68 Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) usually has a mild  
69 clinical presentation in children. However, in rare cases, children can be severely affected and have  
70 clinical manifestations different from adults. In April 2020, some reports described a clinical  
71 syndrome similar to Kawasaki disease or toxic shock syndrome temporally associated with current or  
72 recent SARS-CoV-2 infection in the pediatric population(1). Since then, this syndrome has been  
73 recognized worldwide and named pediatric inflammatory multisystem syndrome (PIMS) or  
74 multisystem inflammatory syndrome in children (MIS-C). (2–6).

75 PIMS case definition varies slightly between different health agencies (7–9) and is likely to change  
76 over time. Criteria include fever, inflammatory marker elevation, multisystem organ involvement,  
77 evidence of current or recent SARS-CoV-2 infection, and exclusion of alternative diagnoses. Besides  
78 the need for hospitalization for life support, an outcome of concern is possible myocardial and  
79 coronary artery involvement similar to those observed in Kawasaki disease (10–12).

80 PIMS incidence has been estimated to be approximately 3-5 per 10,000 individuals younger than 21  
81 years of age infected with SARS-CoV-2. Black and Hispanic ethnicities have been associated with a  
82 higher incidence (13).

83 Epidemiological description of PIMS has been difficult because of varying awareness of the  
84 condition in different clinical scenarios and because of the diversity of clinical manifestations.  
85 Besides, there is an overlap between the clinical manifestations of severe acute COVID-19 and PIMS  
86 (10). Current PIMS case definition is purposely broad and unspecific in the aim to collect the  
87 maximum information about this phenomenon. However, increasing evidence suggests the existence  
88 of different phenotypes of PIMS, the more clearly defined of them being a Kawasaki-like syndrome,  
89 a Toxic Shock-like syndrome, and a predominantly respiratory syndrome which might have different  
90 pathogenesis and clinical outcomes. (14–16).

91 This study aims to describe the clinical characteristics and outcomes of PIMS cases admitted to a  
92 tertiary care pediatric center in Mexico City. An attempt was made to define different subgroups of  
93 patients who otherwise fulfilled case definition criteria for PIMS.

## 94 **Methods**

95 *Study design.* This is a cross-sectional analysis of PIMS cases diagnosed in “Hospital Infantil de  
96 México Federico Gómez” (Federico Gómez Mexico Children’s Hospital), a tertiary care pediatric  
97 facility officially designated to attend patients with severe SARS-CoV-2 infection in the population  
98 younger than 18 without public or private health insurance in Mexico City.

99 Possible PIMS cases were identified in the emergency room, were transferred from other health care  
100 facilities directly to the Intensive Care Unit or were identified by treating physicians in the general  
101 hospitalization ward for COVID-19 patients. Cases were evaluated to determine if they met the CDC  
102 PIMS case definition(7). In brief, criteria included the presence of fever, the elevation of  
103 inflammatory markers, signs of involvement of at least two organic systems requiring hospitalization,  
104 and evidence of recent SARS-CoV-2 exposure or infection. Patients were excluded if they had  
105 another plausible explanation for the illness. When there was uncertainty about an alternative  
106 diagnosis, the complete case file was reviewed by an expert panel which included an infectious  
107 disease and a critical care specialist, and a consensus was reached. Detailed inclusion criteria are  
108 specified in Chart 1.

109 *Data collection.* Clinical and laboratory data were extracted from the clinical file and included  
110 demographics, underlying medical conditions, clinical manifestations, laboratory values,  
111 management, and outcomes. For laboratory values with more than one measurement, the worst value  
112 measured within the first three days of hospitalization was registered. Vital support management  
113 (respiratory support and vasopressor utilization), intravenous immune globulin, systemic steroids,  
114 and anticoagulant therapy were documented as the main therapeutic interventions. Outcomes of  
115 interest were intensive care unit (ICU) admission, length of ICU and hospitalization stay, need for  
116 invasive mechanical ventilation, vasopressor support, myocardial depression (left ventricular ejection  
117 fraction < 55%), coronary aneurysms (coronary artery diameter z-score  $\geq 2.5$ ), or dilatation (z-score  
118  $2 > - < 2.5$ ) on the echocardiographic evaluation performed during hospitalization, and in-hospital  
119 mortality. Markers with more than 20% missing data were not analyzed.

120 For this study, severe respiratory involvement was defined as infiltrates on chest X-ray or computed  
121 tomography plus the need for oxygen administration with a non-re-breathable mask or a higher

122 oxygen concentration device. The variable “gastrointestinal symptoms” was defined as the presence  
123 of at least one of the following: abdominal pain, diarrhea or emesis.

124 The study center has an important population of patients with severe underlying diseases. To have a  
125 picture more alike general population, we performed a sub-analysis with the exclusion of cases with  
126 severe underlying diseases (i.e., cancer and other forms of immunosuppression, neuromuscular  
127 disability, chronic respiratory disease except for asthma, congenital cardiopathies, and chronic kidney  
128 failure).

129 *Statistical analysis.* Descriptive analysis was undertaken in STATA v.14.0 (StataCorp, Tx).  
130 Categorical variables are reported as frequencies and continuous variables as medians and  
131 interquartile ranges (IQR). Analysis was performed in the whole sample and three subgroups. In the  
132 first subgroup, cases with severe underlying conditions were excluded. The other two groups were  
133 derived using latent class analysis (LCA). Two class LCA were conducted using the R software  
134 package “poLCA” (17) with 100 iterations to identify the clusters. The indicator variables used in  
135 LCA were the presence or absence of severe respiratory involvement, rash, and gastrointestinal  
136 symptoms. The fit of each model was assessed using a Bayesian Information Criterion score.

137 The ethics review board of Federico Gómez Mexico Children’s Hospital authorized the analysis and  
138 publication of de-identified data (Reg: HIM2020-031).

## 139 **Results**

140 Clinical departments sent 167 reports of cases with probable PIMS admitted to the Hospital from  
141 May 1, 2020, through September 30, 2021. For reference, during this period, 8193 real time  
142 polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 tests were performed in the study center,  
143 from which 837 had a positive result.

144 From the 167 received reports, 42 were from the emergency department, 34 from the intensive care  
145 unit, and 91 from the infectious disease department. Duplicated reports were eliminated (n=23), 23  
146 reports failed to meet inclusion criteria and 46 were excluded because an alternative etiology was  
147 found to explain the clinical manifestations after the comprehensive review of the case’s file and  
148 consensus among researchers. All subsequent analyses were performed in the remaining 75 cases  
149 unless otherwise specified.

150 The median (interquartile range, IQR) age was 10.9 (5.6-15.6) years old and 52% were female. At  
151 least one underlying condition was found in 45.3% of the population, including obesity (25%),  
152 cancer (9%), neuromuscular (8%), and respiratory (7%) diseases among others (Table 1).

153 In addition to fever, the most common clinical manifestations were cough (52%), conjunctivitis  
154 (50.6%), abdominal pain (51%), rash (48%), headache (45.3%), and diarrhea (44%). The median  
155 (IQR) duration of symptoms before admission was 7 (4-9) days. About 51% had lower respiratory  
156 symptoms, 85% had pulmonary infiltrates in the radiograph or computed tomography, and 65.3%  
157 required oxygen administration with a non-rebreathable mask, high flow nasal cannula, or  
158 mechanical ventilation. Vasopressor support was used in 52% of cases, and about 40% had a left  
159 ventricular ejection fraction < 55% on echocardiography. Median values for markers of  
160 inflammation, coagulation, and system damage are summarized in table 1.

161 Three subgroups were analyzed independently. In the first subgroup (n=60), 15 cases with a severe  
162 underlying disease were excluded. Clinical manifestations and outcomes did not differ significantly  
163 from those observed in the total sample (Table 1 and 2)

164 The second (n=60) and third (n=15) subgroups were derived from LCA which identified two classes  
165 of patients: cluster 1 (n=60) composed of patients with rash and/or gastrointestinal symptoms, and  
166 cluster 2 (n=15) with predominant cardiorespiratory involvement without a rash or gastrointestinal  
167 symptoms. Despite the reduced number of cases in cluster 2, some differences are evident: cluster 2  
168 cases were more prone to have a positive RT-PCR test (76% vs 100%, p= 0.04) and less so to have a  
169 positive serology test (0 vs 54%, p<0.001). An underlying medical condition was also more frequent  
170 in cluster 2 (80 vs 36.7%, p=0.003), especially a severe one (47 vs 13%, p=0.008) such as cancer,  
171 neuromuscular disability, or a chronic respiratory condition. (Table 1). Cluster 1 patients tended to  
172 have higher levels of inflammation markers, though the difference was statistically significant only  
173 for the neutrophil count and D-Dimer concentration.

174 About treatment, 45.3%, 64%, and 63% of cases received intravenous immune globulin, systemic  
175 steroids, and anticoagulation therapy respectively, much more frequently in the cluster 1 group.  
176 (Table 2)

177 Regarding outcomes, two (2.7%) patients died. Both had severe underlying diseases; the first one had  
178 a medulloblastoma and died two weeks after the antineoplastic chemotherapy dose and the second  
179 one had chronic kidney failure and was on dialytic replacement therapy. One death occurred in each  
180 cluster group. About 44% of cases needed mechanical ventilation, 52% of cases required vasopressor  
181 support while 40% had a depressed ventricular function. (Table 2)

182 All cases had an echocardiographic evaluation during hospitalization. Five cases (6.7%) had coronary  
183 aneurysms. Notably, all cases with aneurysms were in Cluster 1. No patient had a coronary diameter  
184 with a z-score between 2.0 and 2.5. Myocardial involvement (left ventricular ejection fraction <  
185 55%) was observed in 30(40%) of cases. Intensive care unit (ICU) admission occurred in 64% of  
186 cases with a median (IQR) length of stay there of 5 (3-8) days and a length of hospital stay of 7(4-  
187 13). There was a tendency of cluster 2 patients to remain longer in ICU and in hospital. (Table 2)

## 188 **Discussion**

189 The present study describes the largest cohort of patients with PIMS in the Mexican population to  
190 date, as long as we are aware. Most clinical characteristics and outcomes of our series were like those  
191 described in large international reports. The median age of our sample was some years older than  
192 most series. Prevalence of underlying medical conditions, including obesity was similar to the  
193 reported in the United States and Latin America (10,16,18–20), except for cancer which is relatively  
194 frequent in our total sample, reflecting the characteristics of the population regularly attending the  
195 study center. Cardiac dysfunction, vasopressor requirements, rash, and gastrointestinal symptoms  
196 were comparable to those reported elsewhere, so as ICU admissions, length of hospital stay, and  
197 length of ICU stay. The death rate of 2.7% (binomial 95% confidence interval: 0.3-9.3%) was similar  
198 to the previously reported (3,5,10,14,18,21).

199 Our population had a relatively high frequency of lower and serious respiratory involvement in  
200 comparison with most of the other series. Besides, in our sample, serology was performed in only  
201 55% of cases, so the evidence of SARS-CoV-2 infection in our population is mostly by RT-PCR  
202 (80% positivity rate). These findings might point toward a higher proportion of acute severe SARS-  
203 CoV-2 infection vs a theoretical late-onset post-infectious syndrome in our sample compared to



204 other case series where respiratory involvement and RT-PCR positive rate was lower (3,5,10,14,18).  
205 Current PIMS diagnostic criteria does not exclude acute severe COVID-19; this overlap between  
206 both clinical presentations has been previously discussed (10,16).

207 On the other hand, the frequency of coronary aneurysms in our study was relatively low (6.7%).  
208 Aneurysm frequency is heterogeneous among reports, varying from 6.7 to 23.3% (14,18,19,21). This  
209 probably reflects the lack of specificity on the PIMS case-definition criteria and the variability of the  
210 cut-point for some inflammatory markers used in different reports. Most case series are derived from  
211 active or passive surveillance, either retrospectively or prospectively. Many of them do not inform a  
212 cut-point for inflammatory markers concentration, or clinical symptoms and it is assumed that the  
213 higher limit of the normal reference range was used. This probably explains the high frequency of  
214 coronary aneurysms (23.3%) found by Flood et al., in the United Kingdom, their study having a very  
215 high cut-point for CRP (100mg/L) and requiring “acute abdomen” and very specific dermatological  
216 findings, not only “abdominal pain” or “rash” as criteria for gastrointestinal or mucocutaneous  
217 involvement respectively (14). Stringency in diagnostic criteria automatically excludes a high  
218 proportion of potential cases keeping a more homogeneous and severely affected population.

219 Notably, none of the five aneurysm cases of our series had a serious underlying disease and all of  
220 them belonged to cluster 1 (Mucocutaneous/gastrointestinal predominant symptoms). Although ours  
221 was a small sample to make any inference, it supports the increasing awareness about the existence of  
222 different clinical phenotypes. Godfred-Cato et al.(15), and later Geva et. al(16), identified three  
223 classes of patients: 1) a seriously ill group with significant cardiovascular involvement, multiple  
224 organ dysfunction, a pronounced elevation of inflammatory markers who tended to have positive  
225 serology for SARS-CoV-2, a second group with predominant respiratory involvement and high RT-  
226 PCR positivity rate that resembles our cluster 2 group, and the third group with predominant  
227 Kawasaki- like mucocutaneous findings. Meanwhile, Flood et al. also identified three PIMS  
228 phenotypes using cluster analysis: PIMS with Kawasaki disease-like presentation, PIMS with  
229 findings of Kawasaki disease and shock, and PIMS without any of these features (14) and consensus  
230 derived clinical recommendations have been generated accordingly (22) . In all three cluster  
231 analyses, coronary artery aneurysms are more frequent in groups with Kawasaki-like features and  
232 higher levels of inflammatory markers, which in our cluster analysis corresponds to Cluster 1. It  
233 might be important to differentiate the clinical subtypes diagnosed as PIMS under the umbrella of  
234 CDC and WHO case definition criteria, since probably not all of them benefit from the same  
235 therapeutic interventions. The role of inflammation along all spectrum of severe illness associated  
236 with SARS-CoV-2 infection should be deeply studied, including its role in myocardial dysfunction  
237 since it is a frequent complication both in adults with COVID-19 and children with PIMS. (23)

238 A limitation of this study, as in others, is the method for identification of included cases for analysis  
239 depending on spontaneous reports by treating clinicians. In the future, a prospective multicentric  
240 cohort design with clear-cut criteria for subclassification of every patient fulfilling the broad clinical  
241 criteria after SARS-CoV-2 infection would provide more information on the outcomes and possible  
242 associated factors.

## 243 **Conclusions**

244 Epidemiology of PIMS cases observed in our center is comparable to the reported elsewhere,  
245 although our series included a high proportion of patients with an acute-like respiratory phenotype.  
246 Coronary aneurysms are infrequent and usually present in previously healthy patients with rash or

247 gastrointestinal symptoms. The death rate is alike the reported elsewhere and occurred in patients  
248 with severe underlying diseases.

249 We agree with other researchers that underneath the umbrella of case definition for criteria for  
250 COVID-19 at least two groups of patients can be identified according to their clinical presentation.  
251 Standardized criteria for sub-classification of PIMS cases need to be developed, since different  
252 phenotypes might have different pathophysiology, different outcomes, and possibly require different  
253 management. Clinical trials are needed to evaluate therapeutic interventions in different PIMS  
254 phenotypes.

### 255 **Conflict of Interest**

256 The authors declare that the research was conducted in the absence of any commercial or financial  
257 relationships that could be construed as a potential conflict of interest.

### 258 **Data Availability**

259 All data produced in the present study are available upon reasonable request to the authors

### 260 **Author Contributions**

261 All authors contributed with study planning, design and review of the final manuscript. RGG ,  
262 MLMY, RNJJ, VBOL contributed with data collection . HMG coordinated the research team. MFCP  
263 and NGG performed data analysis and the writing of the manuscript.

### 264 **Funding**

265 This study was funded by Hospital Infantil de México Federico Gómez

### 266 **Data Availability Statement**

267 The datasets generated for this study can be requested to corresponding authors.

- 268 1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory  
269 shock in children during COVID-19 pandemic. *Lancet*. 2020;395(10237):1607–8.
- 270 2. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem  
271 Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and  
272 Adolescents in New York City. *JAMA - J Am Med Assoc*. 2020;324(3):294–6.
- 273 3. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical  
274 Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome  
275 Temporally Associated with SARS-CoV-2. *JAMA - J Am Med Assoc*. 2020;324(3):259–69.
- 276 4. Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M. SARS-CoV-2 – Induced Kawasaki-  
277 Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children. *Pediatrics*.  
278 2021;146(2):1–5.
- 279 5. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem  
280 Inflammatory Syndrome in Children in New York State. *N Engl J Med*. 2020;383(4):347–58.

- 281 6. Assessment RR. European Centre for Disease Prevention and Control Country Experts. Rapid  
282 Risk Assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection  
283 in children. <https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk->  
284 assessment. 2020;(May):1–18.
- 285 7. HAN Archive - 00432 | Health Alert Network (HAN) [Internet]. [cited 2021 Dec 14].  
286 Available from: <https://emergency.cdc.gov/han/2020/han00432.asp>
- 287 8. Royal College of Paediatrics and Child Health. Guidance paediatric multisystem inflammatory  
288 syndrome temporally associated with Cov-19. *R Coll Paediatr Child Heal*. 2020;1–6.
- 289 9. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem  
290 inflammatory syndrome in children and adolescents. *Lancet Infect Dis*. 2020;20(11):e276–88.
- 291 10. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al.  
292 Characteristics and Outcomes of US Children and Adolescents with Multisystem  
293 Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-19.  
294 *JAMA - J Am Med Assoc*. 2021;325(11):1074–87.
- 295 11. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al.  
296 Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. *N Engl J*  
297 *Med*. 2021;385(1):23–34.
- 298 12. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care  
299 admissions of children with paediatric inflammatory multisystem syndrome temporally  
300 associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet*  
301 *Child Adolesc Heal*. 2020;4(9):669–77.
- 302 13. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of  
303 Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-  
304 CoV-2. *JAMA Netw Open* [Internet]. 2021 Jun 1 [cited 2021 Dec 14];4(6):e2116420–  
305 e2116420. Available from:  
306 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780861>
- 307 14. Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al. Paediatric  
308 multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS):  
309 Prospective, national surveillance, United Kingdom and Ireland, 2020. *Lancet Reg Heal - Eur*  
310 [Internet]. 2021 Apr 1 [cited 2021 Dec 14];3. Available from:  
311 <http://www.thelancet.com/article/S2666776221000521/fulltext>
- 312 15. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-  
313 Associated Multisystem Inflammatory Syndrome in Children - United States, March-July  
314 2020. *MMWR Morb Mortal Wkly Rep* [Internet]. 2020 Aug 14 [cited 2021 Dec  
315 14];69(32):1074–80. Available from: <https://pubmed.ncbi.nlm.nih.gov/32790663/>
- 316 16. Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, et al. Data-driven  
317 clustering identifies features distinguishing multisystem inflammatory syndrome from acute  
318 COVID-19 in children and adolescents. *EclinicalMedicine* [Internet]. 2021;40:09–10.  
319 Available from: <https://doi.org/10.1016/j.eclinm.2021.101112>



- 320 17. Linzer DA, Lewis JB. poLCA: An R package for polytomous variable latent class analysis. *J*  
321 *Stat Softw.* 2011;42(10):1–29.
- 322 18. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic  
323 and Temporal Distribution of US Children with Multisystem Inflammatory Syndrome during  
324 the COVID-19 Pandemic. *JAMA Pediatr.* 2021;175(8):837–45.
- 325 19. States U, July M, Godfred-cato S, Bryant B, Leung J, Oster ME, et al. COVID-19–Related  
326 Multisystem Inflammatory Syndrome in Children. *AAP Gd Rounds.* 2020;44(3):30–30.
- 327 20. Torres JP, Izquierdo G, Acuña M, Pavez D, Reyes F. Multisystem inflammatory syndrome in  
328 children (MIS-C): Report of the clinical and epidemiological characteristics of cases in  
329 Santiago de Chile during the SARS-CoV-2 pandemic Juan. *Int J Infect Dis.*  
330 2020;2020(100):75–81.
- 331 21. Antúnez-Montes OY, Escamilla MI, Figueroa-Urbe AF, Arteaga-Menchaca E, Lavariega-  
332 Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and Multisystem Inflammatory Syndrome  
333 in Latin American Children: A Multinational Study. *Pediatr Infect Dis J.* 2020;40(1):1–6.
- 334 22. Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan A V., et al. A national  
335 consensus management pathway for paediatric inflammatory multisystem syndrome  
336 temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. *Lancet*  
337 *Child Adolesc Heal.* 2021;5(2):133–41.
- 338 23. Eiros R, Barreiro-Pérez M, Martín-García A, Almeida J, Villacorta E, Pérez-Pons A, et al.  
339 Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional  
340 descriptive study in healthcare workers. *Rev Española Cardiol (English Ed.* 2021;

341

<b>Chart 1. Case definition criteria for PIMS</b>	
1. Fever	
2. Elevation of inflammation markers	<p>At least one of the following:</p> <ul style="list-style-type: none"> <li>• C-Reactive Protein (CRP) &gt;5mg/L</li> <li>• Procalcitonin &gt; 0.15 ng/ml</li> <li>• Ferritin &gt; 300 mcg/L</li> <li>• Fibrinogen &gt; 400 mg/dl</li> <li>• D-Dimer &gt;560 ng/ml</li> <li>• Neutrophils &gt; 7500 cells/mcl</li> <li>• Lymphopenia: &lt;2 years: &lt;4000, 2-3 years: &lt; 3000, &gt;4 years: &lt;1500 cells/mcl</li> <li>• Albumin &lt; 3 g/dl</li> </ul>
3. At least two systems involved	<p>3.1 Cardiovascular. At least one of the following:</p> <ul style="list-style-type: none"> <li>• Required vasoactive drug</li> <li>• Left ventricular ejection fraction &lt; 55%</li> </ul> <p>3.2 Respiratory. At least one of the following:</p> <ul style="list-style-type: none"> <li>• Supplementary oxygen with non-rebreathable mask or higher oxygen concentration device.</li> <li>• Oxygen saturation &lt;90%</li> <li>• Pulmonary infiltrates in chest X-Ray or Computed Tomography</li> </ul> <p>3.3 Neurologic. At least one of the following:</p> <ul style="list-style-type: none"> <li>• Glasgow score &lt; 14 if not sedated</li> <li>• Meningismus</li> <li>• Seizures</li> </ul> <p>3.4 Hematologic. At least one of the following:</p> <ul style="list-style-type: none"> <li>• Plateletes &lt; 150 000 cells/mcl</li> <li>• Prothrombin time &gt;14 sec</li> </ul> <p>3.5 Gastrointestinal. At least one of the following:</p> <ul style="list-style-type: none"> <li>• Abdominal pain</li> <li>• Vomit</li> <li>• Diarrhea</li> <li>• Alanineaminotransferase (ALT) &gt; 90 U/L</li> </ul> <p>3.6 Mucocutaneous. At least one of the following:</p> <ul style="list-style-type: none"> <li>• Rash</li> <li>• Extremity edema</li> <li>• Desquamation</li> <li>• Mucosal inflammation</li> <li>• Conjunctivitis</li> </ul> <p>3.7 Renal.</p> <ul style="list-style-type: none"> <li>• Creatinine &gt; twice upper limit of the reference range for age</li> </ul>
4. Hospitalization	
5. No alternative diagnosis	<ul style="list-style-type: none"> <li>• No positive blood culture during the first 48 hours in the hospital</li> <li>• In uncertain cases, complete file review and consensus by an expert panel.</li> </ul>
6. Present or recent infection by SARS-COV2	<p>At least one of the following</p> <ul style="list-style-type: none"> <li>• Positive RT-PCR<sup>1</sup> for SARS-COV2</li> <li>• Positive serology for SARS-COV2</li> <li>• Contact with a confirmed positive COVID-19 case in the last four weeks.</li> </ul>
<sup>1</sup> Reverse transcriptase polymerase chain reaction.	

<b>Table.1 Clinical presentation of cases with PIMS</b>				
	<b>Total population(N =75)<sup>1</sup></b>	<b>Without serious underlying disease<sup>2</sup> (N=60)<sup>1</sup></b>	<b>Cluster 1 With GIS<sup>3</sup> or Rash (N=60)<sup>1</sup></b>	<b>Cluster 2 Predominant respiratory (N=15)<sup>1</sup></b>
Female sex -no.(%)	39 (52%)	33(55%)	33 (55%)	6 (40%)
Age - median (IQR)	10.9 (5.6-15.6)	10.6 (5.5-15.0)	10.3 (5.7-13.5)	15.3 (5.4-16.6)
Age group - n (%)				
<1 y	5 (6.7%)	5 (8.3%)	4(6.7%)	1 (6.7%)
1-4 y	11 (17.3%)	9 (15%)	9 (15%)	2 (1.3%)
5-9 y	13 (17.1%)	11 (18.3%)	12 (0.2%)	1 (6.7%)
10-14 y	26 (34.7%)	21 (35%)	23 (38.3%)	3 (20%)
15-18 y	20 (26.7%)	14 (23.3%)	12 (20%)	8 (53%)
Days of symptoms before admission	7(4-9)	7 (5-9)	6 (4-8)	7 (1-9)
<b>SARS-COV2 testing, No. (%)</b>				
RT- PCR positive	57/ 71 (80%)	43/ 56 (76.8%)	44/58 (75.9%)	<b>13/13 (100%)*</b>
Serology positive	25/ 41 (61%)	25/46 (54%)	25/ 46(54%)	<b>0*</b>
<b>Underlying medical conditions - no. (%)</b>				
Obesity (BMI > 95 <sup>th</sup> percentile)	18 (24%)	14 (23.0%)	12 (20%)	6 (40%)
Respiratory	5 (6.7%)	3 (5%)	2 (3.3%)	<b>3(20%)*</b>
Neuromuscular	6 (8.0%)	0	2 (3.3%)	<b>4 (26.7%)*</b>
Cardiovascular	3 (4%)	0	2 (3.3%)	1 (6.7%)
Cancer	7 (9.3%)	0	2 (3.3%)	<b>5 (33%)*</b>
Other, immunosuppression	2 (3%)	0	1 (1.7%)	1 (6.7%)
Other comorbidity	10 (13.3%)	6 (10%) <sup>4</sup>	8 (13.3%)	2 (13.3%)
At least 1 underlying condition	34 (45.3%)	19 (31.2%)	22 (36.7%)	<b>12 (80%)*</b>
<b>Clinical manifestations – no.(%)</b>				
Cough	39(52%)	32 (53.3%)	33 (55%)	6 (40%)
Rash	36 (48%)	33 (55%)	36 (60%)	0
Conjunctivitis	39 (50.6 %)	39 (52%)	37 (61.7%)	2 (13.3%)
Diarrhea	33 (44%)	27 (45%)	33 (55%)	0
Abdominal pain	38 (51%)	36 (60%)	38 (63.3%)	0
Headache	34(45.3%)	25 (41.7%)	27 (45%)	7 (46.7%)
Rinorrhea	24 (32%)	20 (33.3%)	19 (31.7%)	5 (33.2%)
Respiratory Distress	31 (41%)	24 (40%)	21 (35%)	<b>10 (66.7%)*</b>
Lower respiratory symptoms	41 (54%)	31 (51.7%)	29 (48.3%)	<b>12 (80%)*</b>
Anosmia/Dysgeusia	7 (9.3%)	6 (10%)	4 (6.6%)	3 (20%)
Arthralgias/Myalgias	14(18.7%)	11 (18.3%)	13 (21.7%)	1 (6.7%)
Oxygen Saturation<90%	30 (40%)	20 (33.3%)	22 (36.7%)	8 (53.3%)
<b>Laboratory values within 72 h of admission – median (IQR) / n.(%)</b>				
Neutrophil count x10 <sup>6</sup> cells/mcl	6.1 (1.7-9.2)	7.1(3.1-10.1)	6-5 (1.9-9.8)	<b>3.1(0.5-7.1)*</b>
Neutrophilia (>7500 cels/mm <sup>3</sup> )	29/74 (39.2 %)	27/59 (45.8%)	27/59 (45.8%)	<b>2 (13.3%)*</b>
Neutropenia (<1000 cels/mm <sup>3</sup> )	10 (13%)	6 (10%)	5 (8.3%)	<b>5 (33%)*</b>
Lymphocyte count x10 <sup>6</sup> cells/mm <sup>3</sup>	1.5 (0.5-2.4)	1.6 (0.8-2.1)	1.6 (0.6-2.8)	0.8 (0.4-1.8)
Lymphopenia <sup>5</sup>	43/73 (58.9 %)	33/58 (56.9%)	33/58 (56.9%)	10 (66.7%)
Plateletsx 10 <sup>3</sup> cells/mm <sup>3</sup>	162 (94-250)	166(110-271)	162 (105-235)	162 (43-330)
Fibrinogen, mg/dl	510 (404-668)	558(431-724)	516 (412-671)	510 (361-669)
Fibrinogen> 400 mg/dl	52 (69.3%)	44/56 (78.6%)	43 (71.7%)	9 (60%)
Ferritinmcg/L	617 (407-1370)	559 (380-1110)	604 (417-1150)	1370 (325-6071)
Ferritin> 300 mg/dl	53 (70.1%)	41 (68.3%)	46/55 (83.6%)	7/9 (77.7%)
D-Dimer ng/L	2.6 (1.1-6.5)	2.9(1.2-8.8)	3.5(1.3-9.5)	<b>0.8 (0.5-1.2)*</b>
D- Dimer> 560ng/ml (0.56 ng/L)	66/74 (89.2%)	55 (91.7%)	55/59 (93%)	<b>11/15 (73.3%)*</b>
C-reactive protein (mg/L)	9.8 (4.5-18.9)	13.5 (6.1-19.9)	13.2 (5.9-19.1)	7.3 (0.7-17.7)
C-reactive protein > 5mg/L	47/63 (74.6%)	41/50 (82%)	42/54 (77.8%)	5/9 (55.5%)
Procalcitonin ng/ml	1.85 (0.5-6.3)	1.8(0.47-3.84)	2.1 (1.16-6.4)	0.37 (0.12-6.17)
Procalcitonin > 0.15ng/ml	55/62 (88.7%)	43/50 (86%)	47/51 (92%)	8/11 (72.7%)
Albumin< 3g/dl	45/71 (63.3%)	36/56 (64.3%)	40/57 (70.2%)	<b>5/14 (35.7%)*</b>

<sup>1</sup>N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell.<sup>2</sup>Excluded: cancer, immunodeficiency, neuromuscular, chronic respiratory disease except asthma, congenital cardiopathies, chronic kidney failure.<sup>3</sup>GIS: Gastrointestinal symptoms, includes abdominal pain, diarrhea, emesis.<sup>4</sup>Trisomy 21 (n=1) , Post recent appendectomy (n=2), hypothyroidism (n=2), undernutrition (n=1).<sup>5</sup>Lymphopenia: (<2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl)

\*P<0.05, one-sided Fisher exact test/ Mann-Whitney test for comparison between cluster 1 and cluster 2.

**Table 2. Treatment and outcomes of cases with PIMS**

	Total sample(N=75) <sup>1</sup>	Without serious underlying disease (N=60) <sup>1</sup>	Cluster 1 With GIS or rash (N=60) <sup>1</sup>	Cluster 2 Predominant respiratory (N=15) <sup>1</sup>	p*
Treatment – no. (%)					
Intravenous immune globulin	34(45.3%)	32(53.3%)	33 (55%)	1 (6.7%)*	<b>0.01</b>
Systemic steroids	48 (64.0%)	43 (71.7%)	44 (73.3%)	4 (26.7%)*	<b>0.001</b>
Anticoagulation therapy	47 (62.7%)	40 (66.7%)	41 (68%)	6 (40%)*	<b>0.04</b>
Maximum ventilatory support needed - no (%)					
Non-rebreather mask	8 (10.7%)	7 (11.7%)	1 (1.7%)	1 (6.7%)	
High flow nasal cannula	4 (5.3%)	2 (3.3%)	2 (3.3%)	2 (13.3%)	
Non-invasive mechanical ventilation	4 (5.3%)	4 (6.7%)	4 (6.7%)	0	
Invasive mechanical ventilation	33 (44 %)	25 (41.7%)	25 (41.7%)	9 (60%)	0.16
Any infiltrates in chest Rx or CT	60/71 (85%)	48/56 (85.7%)	45/56 (80%)	15 (100%)	0.06
Severe respiratory involvement <sup>2</sup>	28 (37.3%)	21 (35%)	19 (31.7%)	9 (60%)	<b>0.04</b>
Cardiovascular involvement – no (%)					
LVEF <sup>3</sup> <55%	30 (40.0%)	24 (40%)	22 (36.7%)	8 (53.3%)	0.18
LVEF<45%	6 (8.0%)	5 (8.3%)	6 (10%)	0	0.25
LVEF <35%	0	0	0	0	
Coronary aneurysm (z score > 2.5)	5 (6.7%)	5(8.3%)	5 (8.3%)	0	0.32
Coronary dilatation (z score >2 - <2.5)	0	0	0	0	
Vasopressor support – no (%)	39 (52.0%)	30 (50%)	32 (53.3%)	7 (46.7%)	0.43
Hematologic involvement					
Thromboplastin time > 14 s	37/72 (51.5%)	30 (50%)	39 (65%)	12 (80%)	0.26
Platelets count <150 000 cell/mcl	29 (38.7%)	21 (35%)	24 (40%)	6 (40%)	1.0
Neurologic involvement <sup>4</sup>					
Gastrointestinal involvement	5 (6.7%)	5 (8.3%)	5 (8.3%)	0	0.32
AlanineAminotransferase (ALT) > 90 U/L	60 (80%)	51 (85%)	57 (95%)	3 (20%)	<b>&lt;0.001</b>
Mucocutaneous involvement	21/72 (29.2%)	16/58 (27.6%)	17/58 (29.3%)	4/14( 28.5%)	0.62
Acute Kidney Injury, stage 2 <sup>5</sup>	64 (85.3%)	39 (65%)	58 (96.7%)	6 (40%)	<b>&lt;0.001</b>
Clinical outcomes- no.(%) / median (IQR)	19/74 (25.7%)	26.7%	19 (31.7%)	0	<b>0.01</b>
ICU <sup>6</sup> admission	48 (64%)	37 (61%)	38 (63%)	10 (66.7%)	0.53
Length of ICU stay-d (n=48)	5 (3-8)	4(3-8)	4.5 (3-8.3)	7.5 (3.5-13.5)	0.23
Length of Hospital stay days	7 (4-13)	7(4-11)	7 (4-12)	10 (5-17)	0.31
Died	2 (2.7%)	0	1 (1.7%)	1 (6.7%)	0.36

<sup>1</sup> N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell.<sup>2</sup>Severe respiratory involvement was defined as oxygen requirement and infiltrates in thoracic imaging.<sup>3</sup>LVEF= Left ventricular ejection fraction. <sup>4</sup> Neurologic involvement: seizures (n=3), optic neuritis (n=1), meningismus (n=1), headache not included. <sup>5</sup>Acute Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age. <sup>6</sup> ICU: intensive care unit.

\* Comparison Cluster 1 vs. cluster 2with Fisher exact test/ Mann-Whitney test